Classic Hodgkin lymphoma

IF 3.3 4区医学 Q2 HEMATOLOGY

Hematological Oncology Pub Date : 2023-12-01 DOI:10.1002/hon.3239

Justine Kahn, Bouthaina Dabaja, Susan Wu, Kara Kelly, Leanne Berkahn, Astrid Pavlovsky, Anna Sureda, Ann LaCasce

引用次数: 0

Abstract

Classic Hodgkin lymphoma (HL) is rare disease, with an incidence of approximately 85,000 patients globally per year and a predilection for adolescents and young adults (ages 15–39). Since the introduction of combination chemotherapy in the 1960's and radiation dating back to the early 1900's, therapeutic options and by extension, clinical outcomes have improved dramatically with 5-year overall survival (OS) approaching 90% today. [1](#ref-0001) Advances in understanding HL biology have additionally facilitated development of targeted agents and immunotherapy which have further improved short and long-term outcomes. Despite continued improvements in up-front and salvage therapy, long-term survivors of HL experience several treatment-associated late toxicities, thus, along with efforts to improve therapeutic efficacy, efforts to reduce late effects remain a high-priority in the field.

查看原文本刊更多论文

典型霍奇金淋巴瘤。

经典霍奇金淋巴瘤(HL)是一种罕见的疾病，全球每年的发病率约为85,000例，多见于青少年和年轻人(15-39岁)。自从20世纪60年代引入联合化疗和20世纪初的放射治疗以来，治疗选择和临床结果得到了显著改善，5年总生存率(OS)接近90%。[1](#ref-0001)了解HL生物学的进步也促进了靶向药物和免疫疗法的发展，进一步改善了短期和长期的结果。尽管前期和补救性治疗不断改进，但HL的长期幸存者经历了几种与治疗相关的晚期毒性，因此，在努力提高治疗疗效的同时，努力减少晚期效应仍然是该领域的重中之重。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hematological Oncology 医学-血液学

CiteScore

4.20

自引率

6.10%

发文量

147

审稿时长

>12 weeks

期刊介绍： Hematological Oncology considers for publication articles dealing with experimental and clinical aspects of neoplastic diseases of the hemopoietic and lymphoid systems and relevant related matters. Translational studies applying basic science to clinical issues are particularly welcomed. Manuscripts dealing with the following areas are encouraged: -Clinical practice and management of hematological neoplasia, including: acute and chronic leukemias, malignant lymphomas, myeloproliferative disorders -Diagnostic investigations, including imaging and laboratory assays -Epidemiology, pathology and pathobiology of hematological neoplasia of hematological diseases -Therapeutic issues including Phase 1, 2 or 3 trials as well as allogeneic and autologous stem cell transplantation studies -Aspects of the cell biology, molecular biology, molecular genetics and cytogenetics of normal or diseased hematopoeisis and lymphopoiesis, including stem cells and cytokines and other regulatory systems. Concise, topical review material is welcomed, especially if it makes new concepts and ideas accessible to a wider community. Proposals for review material may be discussed with the Editor-in-Chief. Collections of case material and case reports will be considered only if they have broader scientific or clinical relevance.